Cancer Research Institute Names New Members to Scientific Advisory Council

New members from five different countries join to advance cancer immunotherapy

Sep 10, 2013, 12:48 ET from Cancer Research Institute

NEW YORK, Sept. 10, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit organization committed to developing immune system-based cancer treatments, named 21 new members to its Scientific Advisory Council. During CRI's 60-year history, council members have shaped the direction of cancer immunology research by guiding Cancer Research Institute's research funding strategies.

In the 2013 fiscal year, the council led Cancer Research Institute in creating funding and research priorities for the distribution of its $14.6 million in grants and fellowships. The work of council members has played a significant role in securing CRI's position as the leader in cancer immunology.

"We are incredibly fortunate to have leading scientists and clinicians willing to give their time to advance cancer immunotherapy treatment worldwide," said Jill O'Donnell-Tormey, CEO and director of scientific affairs at the Cancer Research Institute. "Having them available to guide funding to the most promising research is invaluable."

The council is made up of 68 of the world's top immunologists and tumor immunologists, and is led by immunologist James P. Allison, Ph.D., whose pioneering discoveries about immune system regulation made possible powerful new therapeutic strategies that boost and sustain anti-cancer immune responses. Among those currently serving on the Scientific Advisory Council are three Nobel laureates and 27 members of the National Academy of Sciences.

A complete list of the new members, listed alphabetically, follows:

Nina Bhardwaj, M.D., Ph.D.

Vincenzo Cerundolo, M.D., Ph.D.

Mount Sinai School of Medicine

University of Oxford

New York, New York

Oxford, United Kingdom

Jonathan S. Cebon, Ph.D., FRACP

Lisa M. Coussens, Ph.D.

Ludwig Institute for Cancer Research

Oregon Health & Science University

Heidelberg, Australia

Portland, Oregon

Charles G. Drake, M.D., Ph.D.

Stanley R. Riddell, M.D.

Johns Hopkins Medicine

Fred Hutchinson Cancer Center

Baltimore, Maryland

Seattle, Washington

Richard A. Flavell, Ph.D., F.R.S.

Shimon Sakaguchi, M.D., Ph.D.

Yale University School of Medicine

Osaka University

New Haven, Connecticut

Osaka, Japan

Thomas F. Gajewski, M.D., Ph.D.

Ton N. Schumacher, Ph.D.

The University of Chicago

The Netherlands Cancer Institute

Chicago, Illinois

Amsterdam, The Netherlands

Patrick Hwu, M.D.

Craig L. Slingluff Jr., M.D.

The University of Texas MD Anderson Cancer Center

University of Virginia

Houston, Texas

Charlottesville, Virginia

Elizabeth M. Jaffee, M.D.

Mark Smyth, Ph.D.

Johns Hopkins Medicine

Queensland Institute of Medical Research

Baltimore, Maryland

Herston, Australia

Carl H. June, M.D.

Emil R. Unanue, M.D.

University of Pennsylvania

Washington University School of Medicine

Philadelphia, Pennsylvania

St. Louis, Missouri

Michael Karin, Ph.D.

Robert H. Vonderheide, M.D., D.Phil.

University of California, San Diego

University of Pennsylvania

La Jolla, California

Philadelphia, Pennsylvania

Cornelis J.M. Melief, M.D., Ph.D.

Cassian Yee, M.D.

Leiden University Medical Center

The University of Texas MD Anderson Cancer Center

Leiden, The Netherlands

Houston, Texas

Kunle Odunsi, M.D., Ph.D.

Roswell Park Cancer Institute

Buffalo, New York

For more information about CRI's Scientific Advisory Council or a full list of current members, visit To learn about Cancer Research Institute, its mission and the research it supports, go to

About the Cancer Research Institute

The Cancer Research Institute (CRI), established in 1953, is the world's only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 27 members of the National Academy of Sciences, CRI has invested $263 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to

SOURCE Cancer Research Institute